Gentian Diagnostics ASA Logo

Gentian Diagnostics ASA

Develops & manufactures IVD immunoassays for human & veterinary disease diagnostics.

GENT | OL

Overview

Corporate Details

ISIN(s):
NO0010748866
LEI:
5967007LIEEXZXHNM861
Country:
Norway
Address:
Bjørnåsveien 5, 1596 Moss
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Gentian Diagnostics ASA is a global developer and manufacturer of in vitro diagnostic (IVD) reagents. The company specializes in turbidimetric immunoassays designed for major clinical chemistry platforms, aiming to enhance diagnostic efficiency for laboratories. Its product portfolio addresses high-value biomarkers for both human and veterinary medicine, with a focus on kidney disease, cardiac disease, inflammation, and infection. By developing innovative and efficient diagnostic tests, Gentian enables laboratories to reduce costs and deliver faster, more accurate results to support better treatment decisions. The company serves the global market through a network of OEM partners, distributors, and healthcare providers.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-23 10:15
Regulatory News Service
Gentian Diagnostics: Study Confirms the Value of Calprotectin in Early Detectio…
English 102.9 KB
2025-10-23 10:15
Regulatory News Service
Gentian Diagnostics: Study Confirms the Value of Calprotectin in Early Detectio…
English 3.2 KB
2025-10-23 08:00
Investor Presentation
Gentian Diagnostics: Third quarter 2025 report - Attachment: GDASA Q3 25 presen…
English 2.1 MB
2025-10-23 08:00
Quarterly Report
Gentian Diagnostics: Third quarter 2025 report - Attachment: GDASA Interim repo…
English 865.7 KB
2025-10-23 08:00
Earnings Release
Gentian Diagnostics: Third quarter 2025 report
English 3.2 KB
2025-10-16 09:55
Report Publication Announcement
Gentian Diagnostics: Invitation to presentation of third quarter results
English 721 bytes
2025-09-16 08:11
Investor Presentation
Gentian Diagnostics presents at the Pareto Securities Healthcare conference - A…
English 1.3 MB
2025-09-16 08:11
Report Publication Announcement
Gentian Diagnostics presents at the Pareto Securities Healthcare conference
English 683 bytes
2025-07-10 08:00
Interim Report
Gentian Diagnostics: Second quarter 2025 report - Attachment: GDASA Interim re…
English 859.1 KB
2025-07-10 08:00
Investor Presentation
Gentian Diagnostics: Second quarter 2025 report - Attachment: GDASA Q2 25 pres…
English 2.2 MB
2025-07-10 08:00
Earnings Release
Gentian Diagnostics: Second quarter 2025 report
English 2.7 KB
2025-07-03 13:22
Report Publication Announcement
Gentian Diagnostics: Invitation to presentation of second quarter results
English 721 bytes
2025-06-02 16:34
Major Shareholding Notification
Flaggemelding Gentian Diagnostics ASA
Norwegian 495 bytes
2025-05-23 09:39
Major Shareholding Notification
Disclosure of shareholding
English 986 bytes
2025-05-22 08:47
Major Shareholding Notification
Disclosure of large shareholding
English 893 bytes

Automate Your Workflow. Get a real-time feed of all Gentian Diagnostics ASA filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Gentian Diagnostics ASA

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Gentian Diagnostics ASA via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
ChoA Pharmaceutical Co., LTD. Logo
Global manufacturer of OTC medicines and health supplements distributed through pharmacies.
South Korea 034940
CHUGAI PHARMACEUTICAL CO., LTD. Logo
An R&D pharma leader in Japan creating innovative drugs via antibody engineering technology.
Japan 4519
Cinclus Pharma Holding AB Logo
Clinical-stage pharma developing a next-gen P-CAB drug for severe GERD patients.
Sweden CINPHA
Circio Holding ASA Logo
Developing circular RNA vector tech and immunotherapies for gene and cell therapies.
Norway CRNA
CJ Bioscience Logo
Develops microbiome therapeutics for oncology & IBD using an AI drug discovery platform.
South Korea 311690
CKD Bio Corp. Logo
Develops and manufactures probiotics & APIs using fermentation, also offering cGMP CMO services.
South Korea 063160
CMG Pharmaceutical Co., Ltd. Logo
Develops and manufactures prescription drugs, specializing in Oral Thin Film (OTF) technology.
South Korea 058820
co.don AG Logo
Develops personalized cartilage cell transplants for minimally invasive joint repair.
Germany CNW
Compugen Ltd. Logo
Uses AI to discover and develop novel antibody immunotherapies for hard-to-treat cancers.
Israel CGEN
CORESTEMCHEMON Inc. Logo
Develops stem cell therapies & provides preclinical CRO services to pharma & biotech.
South Korea 166480

Talk to a Data Expert

Have a question? We'll get back to you promptly.